GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Days Payable

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Days Payable : 105.06 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Days Payable?

Laboratorios Farmaceuticos Rovi's average Accounts Payable for the three months ended in Dec. 2023 was €110.6 Mil. Laboratorios Farmaceuticos Rovi's Cost of Goods Sold for the three months ended in Dec. 2023 was €96.1 Mil. Hence, Laboratorios Farmaceuticos Rovi's Days Payable for the three months ended in Dec. 2023 was 105.06.

The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Days Payable or its related term are showing as below:

XMAD:ROVI' s Days Payable Range Over the Past 10 Years
Min: 111.26   Med: 135.28   Max: 157.14
Current: 131.31

During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Days Payable was 157.14. The lowest was 111.26. And the median was 135.28.

XMAD:ROVI's Days Payable is ranked worse than
53.04% of 724 companies
in the Biotechnology industry
Industry Median: 148.12 vs XMAD:ROVI: 131.31

Laboratorios Farmaceuticos Rovi's Days Payable declined from Dec. 2022 (173.73) to Dec. 2023 (105.06). It may suggest that Laboratorios Farmaceuticos Rovi accelerated paying its suppliers.


Laboratorios Farmaceuticos Rovi Days Payable Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Days Payable Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127.77 135.07 111.26 135.49 125.28

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 156.43 126.45 129.99 105.06 149.88

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Days Payable

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Days Payable distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Days Payable falls into.



Laboratorios Farmaceuticos Rovi Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Laboratorios Farmaceuticos Rovi's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (123.901 + 107.593) / 2 ) / 337.224*365
=115.747 / 337.224*365
=125.28

Laboratorios Farmaceuticos Rovi's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

Days Payable (Q: Dec. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2023 ) + Accounts Payable (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (113.637 + 107.593) / 2 ) / 96.071*365 / 4
=110.615 / 96.071*365 / 4
=105.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorios Farmaceuticos Rovi Days Payable Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

TiVo Corporation to Announce First Quarter 2020 Results

By Business Wire Business Wire 04-23-2020

27% Upside potentially in Rovi Corporation

By Bavneet Singh Nagpal bavinagpal 03-17-2015

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 96,461 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 29,583 Shares

By GuruFocus Research GuruFocus Editor 01-07-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 02-03-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 529,463 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 200,000 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011